Do analysts recommend RGC or KLRA?

Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 117.01%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kailera Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, RGC or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is RGC or KLRA more profitable?

Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Kailera Therapeutics N/A N/A N/A

Does the media favor RGC or KLRA?

In the previous week, Regencell Bioscience had 13 more articles in the media than Kailera Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Regencell Bioscience's score of 0.06 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDY or KLRA?

Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 117.01%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has better earnings and valuation, RDY or KLRA?

Dr. Reddy's Laboratories has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Reddy's Laboratories $3.58B 3.08 $456M $0.58 22.80 Kailera Therapeutics N/A N/A N/A N/A N/A

Which has better valuation & earnings, ARWR or KLRA?

Kailera Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arrowhead Pharmaceuticals $829.45M 12.54 -$1.63M -$2.15 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Does the media refer more to ARWR or KLRA?

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 4 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Kailera Therapeutics' score of 0.49 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, KLRA or ABVX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is KLRA or ABVX more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Abivax N/A -99.02% -70.26%

Does the media refer more to KLRA or ABVX?

In the previous week, Abivax had 22 more articles in the media than Kailera Therapeutics. MarketBeat recorded 26 mentions for Abivax and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Abivax's score of 0.03 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 3 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, KLRA or PRAX?

Kailera Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Praxis Precision Medicines $8.55M 825.80 -$303.27M -$13.37 N/A

Is KLRA or PRAX more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Praxis Precision Medicines N/A -43.02% -40.22%

Does the media refer more to KLRA or PRAX?

In the previous week, Praxis Precision Medicines had 15 more articles in the media than Kailera Therapeutics. MarketBeat recorded 19 mentions for Praxis Precision Medicines and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Praxis Precision Medicines' score of -0.08 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Kailera Therapeutics (KLRA) Competitors

$19.70 +0.33 (+1.70%)

As of 04:00 PM Eastern

Compare

KLRA vs. RGC, RDY, ARWR, ABVX, and PRAX

Should you buy Kailera Therapeutics stock or one of its competitors? MarketBeat compares Kailera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kailera Therapeutics include Regencell Bioscience (RGC), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Kailera Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Regencell Bioscience had 13 more articles in the media than Kailera Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Regencell Bioscience's score of 0.06 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Kailera Therapeutics	N/A	N/A	N/A

Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 117.01%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kailera Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Kailera Therapeutics beats Regencell Bioscience on 5 of the 7 factors compared between the two stocks.

How does Kailera Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Kailera Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Kailera Therapeutics	N/A	N/A	N/A

In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Kailera Therapeutics. MarketBeat recorded 8 mentions for Dr. Reddy's Laboratories and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Dr. Reddy's Laboratories' score of -0.74 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Negative
Kailera Therapeutics	Neutral

Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 117.01%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Dr. Reddy's Laboratories has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.08	$456M	$0.58	22.80
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Dr. Reddy's Laboratories beats Kailera Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Kailera Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Kailera Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Kailera Therapeutics' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Kailera Therapeutics	N/A	N/A	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals currently has a consensus target price of $87.80, indicating a potential upside of 18.87%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 117.01%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Kailera Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.54	-$1.63M	-$2.15	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 4 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat Kailera Therapeutics' score of 0.49 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arrowhead Pharmaceuticals and Kailera Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Kailera Therapeutics compare to Abivax?

Kailera Therapeutics (NASDAQ:KLRA) and Abivax (NASDAQ:ABVX) are both mid-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Kailera Therapeutics' return on equity of 0.00% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Abivax	N/A	-99.02%	-70.26%

In the previous week, Abivax had 22 more articles in the media than Kailera Therapeutics. MarketBeat recorded 26 mentions for Abivax and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Abivax's score of 0.03 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	3 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral

47.9% of Abivax shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kailera Therapeutics currently has a consensus price target of $42.75, indicating a potential upside of 117.01%. Abivax has a consensus price target of $130.08, indicating a potential upside of 28.12%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kailera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Kailera Therapeutics beats Abivax on 6 of the 9 factors compared between the two stocks.

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Kailera Therapeutics (NASDAQ:KLRA) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Kailera Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-43.02%	-40.22%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 117.01%. Praxis Precision Medicines has a consensus target price of $572.72, indicating a potential upside of 126.15%. Given Praxis Precision Medicines' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Praxis Precision Medicines had 15 more articles in the media than Kailera Therapeutics. MarketBeat recorded 19 mentions for Praxis Precision Medicines and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Praxis Precision Medicines' score of -0.08 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kailera Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Praxis Precision Medicines	$8.55M	825.80	-$303.27M	-$13.37	N/A

Summary

Praxis Precision Medicines beats Kailera Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.55B	$948.41M	$4.26B	$11.99B
Dividend Yield	N/A	4.84%	9.68%	5.57%
P/E Ratio	N/A	1.47	21.73	23.74
Price / Sales	N/A	119.38	161.90	108.00
Price / Cash	N/A	20.06	46.51	37.25
Price / Book	N/A	7.84	30.05	6.78
Net Income	N/A	-$4.04M	$118.48M	$337.51M
7 Day Performance	-15.01%	-2.89%	-3.24%	-2.72%
1 Month Performance	-8.24%	4.38%	0.54%	1.87%
1 Year Performance	N/A	105.81%	12.35%	26.60%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	4.7469 of 5 stars	$19.70 +1.7%	$42.75 +117.0%	N/A	$2.55B	N/A	N/A	145
RGC Regencell Bioscience	0.1554 of 5 stars	$23.90 -0.9%	N/A	N/A	$11.82B	N/A	N/A	10	Gap Up
RDY Dr. Reddy's Laboratories	1.7338 of 5 stars	$13.65 +0.9%	$16.90 +23.9%	-14.6%	$11.38B	$3.58B	23.53	27,811
ARWR Arrowhead Pharmaceuticals	2.7765 of 5 stars	$77.91 -1.4%	$87.80 +12.7%	+334.8%	$10.97B	$829.45M	N/A	400	Positive News
ABVX Abivax	3.481 of 5 stars	$132.63 +2.4%	$137.15 +3.4%	+1,139.7%	$10.57B	N/A	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. RGC, RDY, ARWR, ABVX, and PRAX

How does Kailera Therapeutics compare to Regencell Bioscience?

Summary

How does Kailera Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Kailera Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Kailera Therapeutics compare to Abivax?

Summary

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. RGC, RDY, ARWR, ABVX, and PRAX

How does Kailera Therapeutics compare to Regencell Bioscience?

Does the media favor RGC or KLRA?

Do institutionals and insiders have more ownership in RGC or KLRA?

Which has preferable valuation & earnings, RGC or KLRA?

Is RGC or KLRA more profitable?

Do analysts recommend RGC or KLRA?

Summary

How does Kailera Therapeutics compare to Dr. Reddy's Laboratories?

Do insiders and institutionals have more ownership in RDY or KLRA?

Is RDY or KLRA more profitable?

Does the media prefer RDY or KLRA?

Do analysts recommend RDY or KLRA?

Which has better earnings and valuation, RDY or KLRA?

Summary

How does Kailera Therapeutics compare to Arrowhead Pharmaceuticals?

Is ARWR or KLRA more profitable?

Do insiders & institutionals have more ownership in ARWR or KLRA?

Do analysts rate ARWR or KLRA?

Which has better valuation & earnings, ARWR or KLRA?

Does the media refer more to ARWR or KLRA?

Summary

How does Kailera Therapeutics compare to Abivax?

Is KLRA or ABVX more profitable?

Does the media refer more to KLRA or ABVX?

Do institutionals and insiders have more ownership in KLRA or ABVX?

Do analysts prefer KLRA or ABVX?

Which has preferable earnings & valuation, KLRA or ABVX?

Summary

How does Kailera Therapeutics compare to Praxis Precision Medicines?

Is KLRA or PRAX more profitable?

Do institutionals & insiders have more ownership in KLRA or PRAX?

Do analysts prefer KLRA or PRAX?

Does the media refer more to KLRA or PRAX?

Which has stronger earnings and valuation, KLRA or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools